A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Clinical trial NCT03525678 · COMPLETED
Trial details
- NCT number
- NCT03525678
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-18
- Primary completion
- 2019-06-21
- Enrollment
- 221
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.